webleads-tracker

Global

Maroc | Médecins-labo : Les «cadeaux» interdits !

Seules les conventions à but scientifique ou de recherches seront exemptes de l’application de cette future loi. Mais les parlementaires ont voulu verrouiller le recours aux conventions qui doivent recevoir l’aval du SGG sur un avis de l’Ordre des médecins. Quelle relation entretient l’industrie pharmaceutique avec les professionnels de la santé ? Les députés de la majorité se sont posé la question et leur réponse a été une proposition de loi. Il faut dire que les relations entre médecins et l’industrie pharmaceutique font partie des tabous. Mais la majorité parlementaire compte bien briser ce tabou par le biais de cette …

Read More »

Time for some New Zealand sunshine?

Mandatory disclosure of financial payments was made law in the US in 2010 by the Physician Payment Sunshine Act (PPSA). All payments individual US doctors or their institutions have received are available through OpenPaymentsData. Since the US legislation has been enacted, Australia and European countries have either enacted or begun to enact similar legislation. The situation in New Zealand, however, remains that we do not have a mechanism for disclosure of payments to doctors from industry. Together with colleagues from the University of Auckland, we set out the issues in an editorial in the New Zealand Medical Journal in March …

Read More »

NHS England vs AP-HP : Managing conflicts of interest

Following a string of allegations against potential conflicts of interest in Clinical Commissioning Group contract awards, NHS England has announced a shake-up of its policy within the health service. Incoming changes include new positions for ‘conflicts of interest guardians’, strengthened statutory guidance and a new cross-system task group chaired by NHS England chairman Sir Malcolm Grant. These reforms are the result of months of discussions with senior leaders in CCGs, internal audit colleagues and NHS England’s legal team. The organisation will kick off a four-week consultation during April and will take final guidance to its board in May, with a …

Read More »

Canadian drug companies agree to divulge how much they pay doctors, health groups

Amid ongoing controversy over the fees pharmaceutical companies pay doctors, 10 Canadian-based firms have agreed to divulge how much cash they hand over to physicians and health organizations every year. They say the voluntary program should make the financial ties between pharma and medicine more visible – and help “neutralize” charges of conflict of interest. The firms plan to start publishing statistics on their overall payments to health professionals next year, though will stop short of releasing figures for individual physicians, as now required in the United States. “To us, building trust is fundamental – to actually meet or exceed …

Read More »

TABAC et Transparence : Les dépenses de lobbying dévoilées au grand jour

La Transparence au cœur des relations d’influence de l’industrie du tabac. Focus sur les dispositions de la loi de modernisation de notre système de santé votée le 17 décembre 2015 à l’Assemblée nationale. Le législateur défini largement la liste des acteurs désormais concernés par le dispositif de transparence : – Les fabricants de produits du tabac[1] ; – Les importateurs de produits du tabac ; – Les distributeurs de produits du tabac ; – Les entreprises, les organisations professionnelles et associations les représentant. Ainsi, toutes les entités impliquées dans le secteur du tabac, que ce soit dans un but promotionnel, …

Read More »

GSK confident over end to doctor payments

GlaxoSmithKline has become the first big drugmaker to stop paying doctors to promote its products in response to mounting pressure on the pharmaceuticals industry over conflicts of interest with medical professionals. The UK group will no longer pay medics anywhere in the world to make presentations on its behalf at medical seminars — setting it apart from rivals which still routinely hire senior doctors to educate their peers about drug brands. The new policy, which came into force this week after two years of planning, marks the latest step by GSK to clean up its reputation after a damaging corruption …

Read More »